Autio, K. A., Choudhury, A. D., Gerke, T. A., Arfe, A., Cheng, H. H., McKay, R. R., Antonarakis, E. S., Narayan, V., Zielinski, M. A., Morgans, A. K. (2026). TALENT: A randomized phase 2 study of talazoparib with or without enzalutamide in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) alterations after progression on abiraterone acetate.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps5145